Expert Opinion on the Prescription Practice of Cefpodoxime in the Management of Respiratory Tract Infections in Indian Settings
Journal of Advances in Medicine and Medical Research · pp. 42–49 · Published 18 May 2024
10.9734/jammr/2024/v36i65449Abstract
Background: Cefpodoxime's prodrug form was absorbed and de-esterified by enterocytes to release the active metabolite, and it shows good In vitro activity against bacterial pathogens causing common RTIs. It was unknown, nevertheless, how clinicians considered about cefpodoxime. Objective: To gather expert opinion on the use of cefpodoxime in the management of respiratory tract infections (RTIs) in Indian settings. Methodology: The cross-sectional survey utilized a 19-item, multiple-response questionnaire to gather expert opinions from specialists with expertise in managing RTIs. The survey encompassed questions about current prescription practices, clinical observations, preferences, and experiences related to the use of cefpodoxime in routine settings for RTI management. The data were analyzed using descriptive statistics. Results: Approximately 53% of the clinicians reported prescribing cefpodoxime in cases of upper respiratory tract infections (URTIs), while 44% of them indicated using it for lower respiratory tract infections (LRTIs). Cefpodoxime emerged as the most commonly prescribed antimicrobial agent for treating URTIs, as reported by 86% of the clinicians. Majority (86.02%) of the clinicians favored cefpodoxime as the oral drug of choice for treating acute otitis media. More than half (68.34%) of the clinicians indicated prescribing cefpodoxime for approximately 5 to 7 days in cases of URTIs. The advantages of cefpodoxime, including its broad spectrum, favorable pharmacokinetic profile, and good bacteriological and clinical efficacy, were acknowledged by 65% of clinicians. Conclusion: The survey findings corroborated cefpodoxime as a widely used antibiotic in Indian settings for managing URTIs and acute otitis media. Clinicians reported that its broad-spectrum coverage, favorable pharmacokinetic profile, and clinical efficacy contribute to its popularity in the management of RTIs.
Cited by 2
2 citations reported by external sources — individual citing-article records aren't available to list yet.
Related research
- A New Antibiotic Adjuvant Entity (Ceftriaxone + Sulbactam + Disodium Edetate): An Alternative to Carbapenems for the Management of Intensive Care Unit Infection — shares topic coverage
- The Bacteriology of Discharging Ear (Otitis Media) Amongst Children in Owerri, Imo State, South East Nigeria — shares topic coverage
- Expert Perspectives on Paracetamol for Managing Pediatric Febrile Illness in Indian Settings — shares topic coverage
- Ghanaian Nurse Practitioners' Experiences in Negotiating Antibiotic Prescription Stewardship for Upper Respiratory Tract Infections — shares topic coverage
- The Common Cold: A Comprehensive Review — shares topic coverage
Article metrics
Real usage data collected on this platform.
1
Page views
0
PDF downloads
0
Outbound clicks
2
Citations
Views over time
Views by country
Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".
Traffic sources
Referring site, by host.
Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.